Cornea Research Foundation of America, Indianapolis, IN; and.
Price Vision Group, Indianapolis, IN.
Cornea. 2021 May 1;40(5):541-547. doi: 10.1097/ICO.0000000000002565.
Endothelial keratoplasty has revolutionized the treatment of corneal endothelial dysfunction and lowered the threshold for treatment by providing rapid visual rehabilitation and setting a high standard for safety and efficacy. Over time, endothelial keratoplasty techniques have evolved toward the use of thinner tissue to optimize visual outcomes; refinements have facilitated donor tissue preparation, handling, and attachment; and adaptations have expanded utilization in eyes with challenging ocular anatomy. Despite early concerns about graft longevity, emerging 10-year endothelial cell loss and graft survival data have been encouraging. A shortage of human donor corneas restricts utilization in many areas of the world and is driving a search for keratoplasty alternatives. Further work is needed to expand the donor supply, minimize impediments to adoption, optimize graft survival, and improve refractive predictability.
内皮角膜移植术通过提供快速的视觉康复和设定安全有效的高标准,彻底改变了角膜内皮功能障碍的治疗方法,并降低了治疗的门槛。随着时间的推移,内皮角膜移植技术逐渐向使用更薄的组织发展,以优化视觉效果;改进使供体组织的准备、处理和附着更加方便;并且还适应了在具有挑战性的眼部解剖结构的眼中的应用。尽管早期人们对移植物的长期效果存在担忧,但新兴的 10 年内皮细胞丢失和移植物存活率数据令人鼓舞。人类供体角膜的短缺限制了世界许多地区的应用,因此正在寻找角膜移植的替代方法。需要进一步的研究来扩大供体的供应,减少采用的障碍,优化移植物的存活率,并提高屈光预测性。